Stocks · News reference
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
argenx successfully completed its acquisition of Forte Biosciences for $77.00 per share in cash, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. The acquisition expands argenx's immunology portfolio and supports its Vision 2030 strategy to become a leading immunology innovation company by targeting diseases with limited treatment options.
Read original at globenewswire-incargenx announced a tender offer to acquire Forte Biosciences for $77 per share in cash. The acquisition adds Forte's first-in-class anti-CD122 monoclonal antibody FB102 to argenx's immunology pipeline. The tender offer commenced on August 6, 2026, with an expiration date of August 26, 2026, and is not subject to a financing condition. Forte's Board of Directors has recommended stockholders accept the offer.
Read original at globenewswire-incargenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc. ("Purchaser"), a wholly-owned subsidiary of argenx BV ("argenx"), has commenced a
Read original at benzingaHalper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether insiders are receiving substantial benefits unavailable to ordinary shareholders and whether transaction terms limit competing offers. The investigations cover Forte Biosciences' sale to argenx, Luxfer Holdings' sale to Wynnchurch Capital affiliates, Sanara MedTech's sale to MiMedx Group, and MarketAxess Holdings' sale to Intercontinental Exchange.
Read original at globenewswire-inc